Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Apr;89(4):286-91.
doi: 10.1016/j.contraception.2013.12.011. Epub 2014 Jan 7.

Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa

Affiliations
Observational Study

Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa

Daniel Westreich et al. Contraception. 2014 Apr.

Abstract

Background: Few data exist regarding the effect of hormonal contraception (HC) on incidence and progression of cervical disease (e.g., cervical dysplasia, squamous intraepithelial lesions, cervical intraepithelial neoplasia) in HIV-infected African women.

Study design: We conducted an observational study of HIV-seropositive women in Johannesburg, South Africa. The effect of individual HC types on the incidence and progression of cervical disease was determined using Poisson regression to obtain adjusted incidence rate ratios.

Results: We evaluated 594 HIV-infected women, with median follow-up time of 445 days; 75 of these women were receiving some form of HC (largely DMPA, NET-EN, or COCs) at baseline. Risks of incidence and progression of cervical disease were similar comparing women not receiving HCs to women receiving DMPA, NET-EN, or COCs both individually by HC-type and considering all HC together.

Conclusions: There was no statistically significant effect of particular HC methods or of HC use in general on rates of incidence or progression of cervical disease in this study. These results should reassure us that use of HC is unlikely to substantially increase risks of cervical disease among HIV-positive women.

Keywords: Cervical disease; Combined oral contraceptives; DMPA, HIV, NET-EN.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflict of interest to declare related to this work.

Similar articles

Cited by

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
    1. Appleby P, Beral V, Berrington de Gonzalez A, Colin D, Franceschi S, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370:1609–1621. - PubMed
    1. WHO; WIICoHaCCHI, editor. Centre. Geneva: 2010. [Accessed 16 November 2011]. Human Papillomavirus and Related Cancers: South Africa. Summary Report 2010. http://wwwwhoint/hpvcentre.
    1. UNAIDS. 2009 AIDS Epidemic Update. Geneva: 2009. http://wwwunaidsorg/en/dataanalysis/epidemiology/2009aidsepidemicupdate/
    1. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, Huh WK, Lyon MD, et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer. 2007;96:1480–1483. - PMC - PubMed

Publication types

Substances